Company: ENTXW
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001178913-25-001674
Chunk: 60

Company: Entera Bio Ltd.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 8
Chunk 60
---
.0 million, representing a purchase price per share equal to approximately $2.17, which was the volume weighted average price per share for the 30 trading days immediately preceding the date of the 2025 Collaboration Agreement.

              13ENTERA BIO LTD.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except share and per share data)(Unaudited) 
            
            NOTE 5 - COLLABORATION AND RESEARCH AGREEMENTS (Cont.)

          OPKO has agreed to a customary lockup with respect to such shares, and may not sell or otherwise transfer them for a period of 12 months following the date of the 2025 Collaboration Agreement, and OPKO has additionally agreed to a customary “standstill” provision, pursuant to which, for a 24-month period following the date of the 2025 Collaboration Agreement, OPKO may not acquire additional equity in the Company or otherwise take certain other actions, in each case without the Company’s consent.
           
          The Company has agreed to use the proceeds from the sale of the foregoing ordinary shares solely to fund its development cost obligations under the 2025 Collaboration Agreement, and has entered an escrow arrangement, together with OPKO and an escrow agent, into which such proceeds in an amount of $8,000 have been deposited. Such proceeds are and presented under restricted cash in the condensed consolidated balance sheet and will be disbursed to fund such development costs.  If the 2025 Collaboration Agreement expires or is terminated for any reason, any funds remaining in such escrow will be disbursed to the Company.
           
          The Company determined that the 2025 Collaboration Agreement is a collaboration agreement under the scope of ASC 808, as the parties thereto are active participants and exposed to the risks and rewards of the collaborative activity.
           
          The consideration received for the ordinary shares issued to OPKO under the 2025 Collaboration Agreement was allocated to the collaboration component of such and the equity component. The Company recognized as equity the fair value of the ordinary shares issued to OPKO net of issuance costs (issuance costs of $75) based on the fair value of the Company's ordinary shares as of the market close on the agreement date. The remaining consideration was allocated to the collaboration component and presented under current other payables (an amount of $295) and Other long-term liabilities (an amount of $515) in the condensed consolidated balance sheet and will be recognized as the program is